Nixon Peabody
Bank of America
You are here:  Home  >  Biotech  >  Current Article

Atara’s net loss exceeds analyst estimates

By   /   Thursday, August 8th, 2019  /   Comments Off on Atara’s net loss exceeds analyst estimates

    Print       Email
Atara Biotherapeutics reported a $74.3 million net loss, or $1.60 per share for the second quarter, a 46 percent increase from the previous second quarter and 10 cents higher than analyst estimates. The company spent $52.3 million on research and development during the period, up 56.5 percent from the second quarter of 2018. General and…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Movegreen makes LA, Orange County acquisitions

Read More →